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ABSTRACT
Aim. To assess the influence of hemoglobin (Hb) levels in
locally advanced head and neck cancer (LAHNC) patients
treated with surgery and postoperative radiotherapy
(PORT).
Material and Methods. Pre- and postoperative Hb levels
were collected in 79 patients treated with surgery followed
by accelerated PORT for LAHNC. Median follow-up was
52 months (range 12–95 months).
Results and Discussion. Four-year overall survival (OS)
rate was 51%. Neither pre- nor postoperative Hb level
(\120 or 130 g/l in women or men, respectively) influ-
enced the outcome. However, when Hb decrease between
pre- and postoperative Hb values was taken into account, 4-
year OS was significantly higher in patients with Hb dif-
ference less than 38 g/l (quartile value) compared with
those with Hb decrease 38 g/l or more (61% versus 16%,
P = 0.008).
Conclusion. Decrease in Hb level by more than 38 g/l
after surgery secondary to blood loss influences the out-
come when postoperative RT is indicated.
Despite the various strategies tried to improve the out-
come, locoregional failure is still high in locally advanced
head and neck cancer patients (LAHNC). Tumor stage,
lymph node involvement, and extranodal extension (ENE)
are well-known prognostic factors. Moreover, numerous
studies pointed out that low hemoglobin (Hb) levels before
and during radiation therapy (RT) were associated with worse
local control and survival in the various types of cancer.1–3
Head and neck cancer patients are at high risk for
developing anemia. Extensive radical surgery, being one of
the important reasons, may cause high intraoperative blood
loss. Furthermore, multimodality therapy such as con-
comitant chemo- and RT, which improve patient survival,
can worsen debilitating anemia. Direct association between
tumor hypoxia and anemia is unclear, but anemia leads to
decreased cell oxygenation and has been shown to con-
tribute to tumor resistance to RT or chemotherapy via
deprivation of the oxygen essential for the cytotoxic
actions of these agents.4 Most studies report on the prog-
nostic importance of the Hb level after primary RT with or
without chemotherapy.5–7 However, there is no published
study assessing the role of decreasing Hb because of blood
loss during surgery on the outcome when postoperative RT
(PORT) is indicated.
Herein, we report the influence of pre- and postoperative
Hb levels, and the amount of its decrease, in LAHNC
patients treated with surgery and PORT.
PATIENTS AND METHODS
Between December 1997 and June 2002, 79 consecutive
patients treated with curative surgery followed by
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accelerated PORT were included in this retrospective
study. Inclusion criteria consisted of nonmetastatic head
and neck cancer classified pT1–pT4 and/or pN0–pN3, age
18 years or older, no previous history of cancer other than
nonmelanoma skin cancer or in situ cervix cancer, and
good performance status World Health Organization
(WHO) scale 0–1 Patients with gross residual disease after
surgery, previous RT with or without systemic chemo-
therapy, metastatic disease or known cause of anemia were
excluded. The majority of patients were male (male-to-
female ratio 62/17). Median age was 60 years (range 36–
81 years). Patient characteristics are listed in Table 1.
All patients were seen and discussed at our multidisci-
plinary tumor board, and the treatment recommendation
was made jointly by head and neck surgeon, radiation
oncologist, and medical oncologist with advice from the
pathologist, diagnostic radiologist, nursing staff, nutri-
tionists, and dentists. Percutaneous endoscopic gastrostomy
(PEG) was placed before or at the beginning of treatment in
24 of 79 patients (30%), and 6 patients (8%) required
nasogastric feeding tube during their treatment.
Pretreatment evaluation included a medical history,
physical examination, panendoscopy and biopsy, computed
tomography (CT) and/or magnetic resonance imaging
(MRI) of the head and neck region in all cases. Additional
diagnostic procedures for distant metastases, including CT
scan of the chest, liver ultrasound, bone scintigraphy, and/
or, more recently, positron emission tomography were only
performed if clinically indicated. T- and N-classification
were assigned according to the staging system of the
International Union against Cancer (UICC) 2002.8
Statistical Methods
Overall survival (OS), disease-free survival (DFS), and
cancer-specific survival (CSS) rates as well as actuarial
locoregional control (LRC) rates were calculated using the
product-limit method.9 Time to any event was measured
from the date of pathological diagnosis. The events were
death (all causes) for OS, head and neck cancer-related
mortality for CSS, and death (all causes) or relapse for
DFS. For the LRC rate, the event consisted of local and/or
regional relapse. Confidence intervals (CI) were calculated
from standard errors. Differences between groups were
assessed using the log-rank test.10 Multivariate analyses
were done using the Cox stepwise-regression analysis to
determine the independent contribution of each prognostic
factor.11
RESULTS
All patients underwent primary curative surgery. PORT
was indicated for positive surgical margins (n = 18) or for
pT4 tumors (n = 3) in 21 (27%) patients, or because of
extranodal infiltration with (n = 29) or without (n = 25)
positive surgical margins in 54 (68%) patients. Four
patients (5%) with three or more positive nodes were also
included. Total dose to the spinal cord was limited to
46 Gy. Median RT duration was 39 days (range 35–
59 days). The interval between surgery and radiotherapy
was B42 days in 51 patients (65%) and [42 days in 28
patients (35%).
Conformal three-dimensional (3D)-RT planning was
used in all patients. Patient immobilization was accom-
plished with individualized thermoplastic masks. The boost
volume (66 Gy) consisted of the clinical target volume
(CTV1), which was defined according to the presurgical
location of the primary tumor and its nodal extension
including the entire surgical bed; and the planning target
volume (PTV1) included a 5-mm margin around the CTV1
in three dimensions. This volume was treated every Friday
afternoon during the first 5 weeks, and daily during the first
3 days of the sixth week. The initial treatment volume
TABLE 1 Characteristics of 79 patients
Number %
Tumor site
Oral cavity 23 29
Oropharynx 23 29
Hypopharynx 17 21
Larynx 6 8
Other 10 13
RT indications
ENE with PSM 29 37
ENE without PSM 25 31
PSM 18 23
Positive LN C3 4 5
pT4 3 4
PT-classification
0 5 6
1 10 13
2 30 38
3 15 19
4 19 24
PN-classification
0 11 14
1 15 19
2a 11 14
2b 27 34
2c 5 6
3 10 13
ENE extracapsular nodal extension, PSM positive surgical margin,
LN lymph nodes
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(PTV2; 50 Gy), which was treated once daily during the
first 5 weeks, consisted of the boost volume and all nodal
areas at risk of subclinical malignant disease (CTV2)
including a 5-mm margin around the CTV2 in three
dimensions. The irradiation source was either a telecobalt
unit or a linear accelerator using 6-MV photons and
electrons.
Pre- and postoperative Hb levels were collected in all
patients. While no information was available concerning
the amount of blood loss during surgery, none of the
patients required blood transfusion due to surgery. In this
study, Hb cut-off value was considered\120 g/l in women
and \130 g/l in men. The median Hb level before surgery
was 138 g/l (range 98–174 g/l), and after surgery 109 g/l
(range 74–161 g/l). The distribution of the Hb value
according to gender is shown in Table 2. A median
decrease of 24 g/l of Hb (quartile values 9 and 38 g/l) was
observed between pre- and postoperative Hb levels (range
-44–68 g/l).
After median follow-up period of 52 months (range
12–95 months), 39 of 79 patients were alive with (n = 1)
or without (n = 38) evidence of disease. Median time to
locoregional relapse (n = 16) was 14 months (range
4–68 months). Median time to distant metastases (n = 19)
was 16 months (range 3–48 months).
The 2- and 4-year OS, CSS, and DFS rates were 65%
(95% CI: 54–76%) and 51% (95% CI: 39–63%), 71%
(95% CI: 60–82%), and 60% (95% CI: 48–72%), and 61%
(95% CI: 49–73%) and 48% (95% CI: 35–60%), respec-
tively (Fig. 1). The 2- and 4-year actuarial LRC probability
was 94% (95% CI: 88–100%) and 79% (95% CI: 69–89%),
respectively. Distant metastases were observed in 19 (24%)
patients, with the probability of being without distant
metastases at 2 and 4 years being 79% (95% CI: 69–89%)
and 67% (95% CI: 55–79%), respectively.
In univariate analyses, gender, age, tumor site, Hb val-
ues before and after surgery, pT- and pN-classification,
presence of ENE, interval between surgery and PORT,
total RT time, and amount of Hb decrease were analyzed.
T-classification, ENE, and decreasing Hb more than 38 g/l
were statistically significant prognosticators on univariate
analyses (Table 3; Fig. 2). T-classification and ENE
remained independently significant in multivariate analyses
(Table 4) for OS, DFS, and CSS. Hb decrease more than
38 g/l was also an independent factor influencing the CSS
(Table 4). No factor influencing the LRC was found in
either univariate or multivariate analyses.
There was no correlation between T- or N-classification
and the amount of Hb decrease following surgery (9 of 45
patients with T1–T2 tumors and Hb decrease B38 g/l
versus 9 of 34 patients with T3–T4 tumors and Hb
decrease[38 g/l, P = 0.50; and 9 of 26 patients with N0–
N1 disease and Hb decrease B38 g/l versus 9 of 53 with
N2–N3 disease and Hb decrease[38 g/l, P = 0.09).
DISCUSSION
Locoregional control is currently the most important
issue in the treatment of LAHNC, and locoregional
recurrence translates directly into poor overall survival.12,13
Several treatment-specific factors (e.g., total radiation dose,
overall treatment time, interval between surgery, and RT)
and patient-specific characteristics (e.g., age, sex, perfor-
mance status, anemia, stage, ENE, and surgical margin) are
known to influence the probability of local tumor control
by RT alone or with surgery. Patients with positive surgical
margins, perineural invasion, lymph node involvement,
presence of ENE constitute a subgroup of patients with
TABLE 2 Hemoglobin status in 79 patients
Preoperative Postoperative
Median (g/l) 138 109
Range (g/l) 98–174 74–161
Number (%) Number (%)
Men (g/l)
\130 21 (27) 48 (61)
C130 41 (52) 14 (18)
Women (g/l)
\120 4 (5) 11 (14)
C120 13 (16) 6 (7)
1.0
0.8
0.6
0.4
0.2
60
MonthsPatients
at Risk
4812 24 360
79
79
79
79
43
43
40
42
62
62
59
60
36
36
32
33
13
13
13
13
28
28
25
27
Percent
Probability
Cancer specific survival
Overall survival
Disease-free survival
Locoregional failure
FIG. 1 Probability of cancer-specific survival (dashed line), overall
survival (solid line), disease-free survival (dotted line), and locore-
gional failure (dashed/dotted line) in 79 patients treated with
accelerated postoperative radiotherapy
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high risk of locoregional relapse.14–18 Besides all of these
prognostic factors, numerous reports have pointed out the
prognostic value of anemia and the adverse effects of
tumor hypoxia on the efficacy of anticancer treatments in
recent years, indicating that decreased radiosensitivity
resulting from tumor hypoxia was the most likely expla-
nation.1–4,19 Recently Rades et al. analyzed 153 LAHNC
patients; they found performance status, stage, surgery,
TABLE 3 Univariate analyses
n 4-yr
OS
95%
CI
P-
value
4-yr
DFS
95%
CI
P-
value
4-yr
CSS
95%
CI
P-
value
4-yr
LRC
95%
CI
P-
value
All patients 79 51 39–63 48 35–60 60 48–72 79 69–89
Gender
Female 17 68 44–90 0.38 62 37–87 0.35 77 53–100 0.29 71 46–96 0.65
Male 62 48 34–62 44 30–58 56 42–70 81 70–92
Age (years)
\60 43 50 42–68 0.35 46 28–64 0.47 54 38–70 0.54 76 62–90 0.74
C60 36 52 34–70 49 31–67 68 50–86 84 71–97
Tumor site
Oral cavity 23 59 39–79 0.93 47 25–69 0.86 65 45–85 0.99 86 71–100 0.57
Oropharynx 23 49 28–70 45 24–66 56 34–78 72 53–91
Larynx/hypo. 23 50 25–75 50 27–73 57 31–83 7 3 49–97
Other 10 50 15–85 50 15–85 57 20–94 83 53–100
T-classification
pT1–2 45 57 41–73 0.03 59 43–75 0.07 63 47–79 0.06 83 72–94 0.51
pT3–4 34 44 26–62 30 12–48 55 36–74 71 52–90
N-classification
pN0–1 26 55 33–77 0.35 46 24–68 0.44 69 50–88 0.40 75 57–93 0.62
pN2–3 53 49 35–63 48 34–52 55 39–71 81 69–93
ENE
No 26 73 54–92 0.03 57 35–79 0.04 87 73–100 0.01 87 73–100 0.16
Yes 53 40 26–54 38 23–53 45 29–61 74 60–88
Surgery–RT interval
(days)
B42 days 51 50 34–66 0.96 47 31–63 0.92 55 37–73 0.59 79 67–91 0.94
[42 days 28 53 37–69 49 30–68 68 48–88 79 62–96
RT duration (days)
B39 days 54 49 35–63 0.58 43 29–57 0.46 54 38–70 0.15 76 63–89 0.58
[39 days 25 57 35–72 57 35–79 73 53–93 84 68–100
Hb (g/l) before surgery
Lowa 25 56 34–78 0.95 53 31–75 0.97 65 42–88 0.75 86 68–100 0.33
Highb 54 50 43–57 47 33–61 58 44–72 75 63–87
Hb (g/l) after surgery
Lowa 59 53 39–67 0.89 47 33–61 0.89 60 56–74 0.78 79 67–91 0.95
Highb 20 46 23–69 46 23–69 59 46–82 77 57–97
Hb decrease (g/l)
Median B24 43 60 44–76 0.15 56 40–72 0.32 72 56–88 0.04 80 66–94 0.94
[24 36 41 23–59 37 19–55 46 28–64 77 62–92
Quartile B38 61 61 47–75 0.008 56 42–70 0.02 70 56–84 0.005 80 69–91 0.59
[38 18 16 0–36 17 0–36 24 0–50 74 52–96
a Low \120 g/l in women and \130 g/l in men
b High C20 g/l in women and C130 g/l in men
OS overall survival, DFS disease-free survival, CSS cancer-specific survival, LRC locoregional control, CI confidence interval, RT radiotherapy,
ENE extracapsular nodal extension
1334 B. Pehlivan et al.
pre-radiotherapy Hb level, and interruptions during
RT [1 week were important prognostic factors for out-
come of radiochemotherapy treatment.20 Three-year LRC
was 46% and 75% in the Hb \12 g/dl and Hb C12 groups.
As reported in the literature, in this study univariate and
multivariate analyses showed that tumor stage and ENE
were significant prognostic factors for OS, DFS, and CSS
(Table 3). Besides all of these factors, univariate analyses
showed that Hb decrease more than 38 g/l during surgery
was also a prognostic factor. Four-year DFS, OS, and CSS
were 56%, 61%, and 70% in patients with Hb decreased
38 g/l or less compared with 16%, 16%, and 24% in
patients with Hb decreased more than 38 g/l. However,
presurgery or pre-RT Hb value did not show any significant
influence on DFS, OS, or CCS (Table 3).
During major surgery, substantial blood loss is possible,
varying between mean values of 500 and 1,500 ml, and
amount of this loss may be depending on disease stage,
tumor size, or any other surgical parameters.2,21 In our
study, neither tumor size nor nodal status was correlated
with the Hb decrease. Twenty percent of patients with T1–
T2 tumors had an Hb decrease of B38 g/l, whereas 26% of
the patients with T3–T4 an Hb decrease of [38 g/l.
Confirming explanations might be based on radiobio-
logical theories. Tumor hypoxia may induce proteomic and
genomic changes, and they may result in clinically more
aggressive tumors with increased potential of metastases
through cellular process.22 Hypoxia induces the expression
of various angiogenic cytokines [vascular endothelial
growth factor (VEGF), basic fibroblast growth factor
(bFGF), interleukin-8 (IL-8), tumor necrosis factor (TNF),
etc.], responsible in the course of various signal transduc-
tion cascades for the proliferation, migration, and
differentiation of the endothelial cells responsible for the
development of neovasculature in a tumor.23 Furthermore,
hypoxia gives rise to inhibition of cellular proliferation by
an accumulation of cells in phase G0 of the cell cycle. It
reduces cytotoxicity, induces hypoxic stress proteins,
lowers the apoptotic potential, and causes tissue acidosis.24
All these factors released under hypoxic conditions may
result in a malignant phenotype of residual tumor cells left
after surgery; and may, therefore, lead to a more aggressive
regrowth of these cells resulting in recurrences.
A number of clinical studies aimed to increase the
outcome by increasing the Hb level by either blood trans-
fusions or recombinant erythropoietin (rEPO). There is,
currently, no clear evidence that correction of anemia
improves prognosis. Henke and colleagues prospectively
compared anemic head and neck cancer patients receiving
definitive RT or PORT with or without rEPO treatment.25
They reported that rEPO treatment corrected hemoglobin
levels, however, had negative impact on locoregional
cancer control and survival. Recently, Overgaard et al.
presented the results of the DAHANCA 10 randomized
trial.26 In this study, 515 patients with Hb values below
9.0 mmol/l (14.0 g/dl) treated with definitive RT were
randomized to receive darbopoietin together with acceler-
ated RT. They observed a significant correction of the Hb
level with darbopoietin in patients with LAHNC resulting,
however, in a significantly poorer locoregional control after
1.0
0.8
0.6
0.4
0.2
60
MonthsPatients
at Risk
4812 24 360
61
18
38
7
48
16
33
4
12
2
26
3
Percent
Overall Survival
38 g/l
> 38 g/l
p = 0.008
Hb decrease
FIG. 2 Overall survival according to hemoglobin (Hb) decrease
following surgery. Solid line represents patients with Hb decrea-
se B38 g/l, and dashed line patients with Hb decrease[38 g/l (log-
rank test, P = 0.008)
TABLE 4 Multivariate analyses
Parameter Overall survival Disease-free survival Cancer-specific survival Locoregional control
RR P-value RR P-value RR P-value RR P-value
T-classification (pT3–4
versus pT1–2)
1.47 0.02 1.38 0.05 1.49 0.04 NS
Extranodal extension
(yes versus no)
1.59 0.01 1.52 0.02 1.82 0.005 NS
Hb decrease (g/l)
([38 versus B38)
1.39 0.07 1.35 0.09 1.49 0.05 NS
RR risk ratio, NS not significant
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RT (56% versus 69%, P = 0.02). The use of darbopoietin
resulted in an increased Hb value in more than 91% of the
patients. However, there was no significant difference in
terms of overall survival (38% versus 51%, P = 0.08).
Primary surgery and PORT is a traditional approach for
operable LAHNC patients. Success of the RT may be
compromised by the presence of demonstrably unfavorable
factors. Surgical procedures and reconstruction frequently
result in high intraoperative blood loss. This study shows
that perioperative Hb decrease may influence the outcome of
the patients who are candidates for PORT. Given negative
anemia-correction studies using rEPO, strategies to prevent
perioperative Hb decrease should focus on limiting blood
loss during surgery. Alternative intraoperative techniques to
minimize bleeding, intraoperative or postoperative blood
transfusion, and investigation of other pharmacologic agents
are warranted.
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